Federman & Sherwood Investigates Salix Pharmaceuticals, Ltd. for Possible Violations of Federal Securities Laws

OKLAHOMA CITY--()--The law firm of Federman & Sherwood has launched an investigation into Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) (“Salix”) for possible violations of federal securities laws.

On November 6, 2014 Salix announced disappointing financial results for the third quarter 2014 which included a $88.6 million net loss. Salix also announced the resignation of Adam Derbyshire as its chief financial officer. Early reports indicate that Mr. Derbyshire’s resignation was related to an accounting scandal involving levels of key gastrointestinal drugs, forcing a reduction in Salix’s financial forecasts for the remainder of the year. On this news, Salix’s shares fell $50.33 per share to $88.22 per share in after-hours trading.

If you invested in Salix’s securities prior to November 7, 2014 or have information to assist in our investigation; or, have any questions or concerns regarding this notice or preservation of your rights, please contact our office. Federman & Sherwood has extensive nationwide experience in representing investors in securities, derivative and merger-related shareholder class actions, and has been appointed as lead counsel in multiple complex cases.

Contacts

Federman & Sherwood
Robin Hester, 405-235-1560
rkh@federmanlaw.com

Recent Stories

RSS feed for Federman & Sherwood

Release Summary

Federman & Sherwood Investigates Salix Pharmaceuticals, Ltd. for Possible Violations of Federal Securities Laws

Federman & Sherwood